DOCSLIB.ORG

2698 Expression Pattern and Targeting of HER Family Members and IGF-IR In

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2698 Expression Pattern and Targeting of HER Family Members and IGF-IR In [Frontiers in Bioscience 17, 2698-2724, June 1, 2012] Expression pattern and targeting of HER family members and IGF-IR in pancreatic cancer Nikolaos Ioannou1, Alan M. Seddon1, Angus Dalgleish2, David Mackintosh1, Helmout Modjtahedi1 1School of Life Sciences, Kingston University London, Kingston, UK, 2Department of Cellular and Molecular Medicine, St George's University of London, London, UK TABLE OF CONTENTS 1. Abstract 2. Introduction 3. HER/ErbB family members and their ligands in pancreatic cancer 3.1. Structure and function of HER/ErbB family members and their ligands 3.2. Expression pattern and prognostic significance of EGFR (HER-1) and its ligands in pancreatic cancer 3.3. Expression pattern and prognostic significance of HER-2 in pancreatic cancer 3.4. Expression pattern and prognostic significance of HER-3 and HER-4 in pancreatic cancer 4. HER family of receptors as therapeutic targets in pancreatic cancer 4.1. EGFR targeting 4.1.1. Anti-EGFR mAbs 4.1.1.1. Cetuximab 4.1.1.2. Panitumumab 4.1.1.3. Matuzumab. 4.1.1.4. Nimotuzumab 4.1.2. EGFR Tyrosine kinase inhibitors 4.1.2.2. Erlotinib 4.1.2.3. Gefitinib 4.2. HER-2 targeting 4.3. HER-3 targeting 4.4. Dual and Pan-HER inhibitors 5. Predictive value of EGFR for response to EGFR inhibitors 6. Mechanisms of resistance to EGFR targeted therapy in pancreatic cancer 6. 1. The role of EGFR mutations in drug resistance. 6. 2. Activation of downstream pathways in an EGFR-independent manner 6. 3. Activation of alternative pathways 7. IGF-IR signalling system in pancreatic cancer 7.1. Expression and prognostic significance of IGF signalling system in pancreatic cancer 7.2. Targeting of IGF signalling system in pancreatic cancer 8. Perspective 9. Acknowledgments 10. References 1. ABSTRACT strategies. Such strategies could ultimately help to overcome the development of drug resistance and Pancreatic cancer is still one of the most improve the overall survival rates for patients with aggressive and fatal types of human cancer . Survival pancreatic cancer. rates for patients with pancreatic cancer are extremely poor and one major contributing factor is the lack of 2. INTRODUCTION specific marker(s) for the early detection of pancreatic cancer. Indeed, the great majority of pancreatic cancer Pancreatic cancer is one of the deadliest human cases are diagnosed at an advanced stage of the disease cancers and a major health problem worldwide. There were and these patients often have a poor response to an estimated 277.000 new cases of pancreatic cancer and treatment with conventional forms of therapy. In this 266.000 deaths from this cancer globally in 2008 (1). article, we conduct a comprehensive review of the Despite the introduction of new therapies in the last two literature on the expression pattern, prognostic decades, the collective median survival rate for patients significance and predictive value of EGFR family with pancreatic cancer remains poor and is less than 6 members, IGF-IR and their ligands in pancreatic cancer. months (2, 3). Several factors have been associated with an We also discuss recent advances in pancreatic cancer increased risk of developing pancreatic cancer including treatments and highlight the remaining challenges as age (above the age of 50), male sex, smoking, presence of well as future opportunities for more effective targeting medical conditions like diabetes and chronic pancreatitis, of such receptors using a combination of growth factor family history, occupational exposure to carcinogens, race receptor specific monoclonal antibodies, small molecule (higher incidence in black population) and high caloric tyrosine kinase inhibitors and other therapeutic consumption/obesity (4). 2698 HER family members and IGF-IR in pancreatic cancer There are numerous histological sub-types of survival, differentiation and apoptosis (16). In contrast to pancreatic cancer but the most common (90%) and hormones, growth factors are secreted by almost all tissues aggressive type is pancreatic ductal adenocarcinoma. The and mediate their effects by binding to their cell surface majority of pancreatic lesions (60-70%) arise in the head, receptors via paracrine, autocrine and/or juxtacrine neck or the uncinate process of the pancreas and the processes (17, 18). Activation of the cellular receptors by remaining 5-10% and 10-15% of all cases occur in the body their respective ligands results in the generation of signals and tail respectively (5). The high mortality rate that which are carried out by several intracellular signalling accompanies this type of cancer is mainly due to the proteins, ultimately leading to the different biological presence of metastases in the majority of patients at the responses by the activation and/or repression of specific time of diagnosis. Since symptoms of the disease don’t sets of genes (18). Since the early 1990s, aberrant usually arise until the cancer is at an advanced stage, most expression and activation of growth factor receptor of the cases (85-90%) are considered to be unresectable and signalling pathways has been reported in a wide range of therefore the only therapeutic option available is palliative human cancers and in some cases has also been associated treatment (3). Indeed, of all pancreatic cancer cases, only 7.5% with a poorer prognosis (17, 19). Such advances have of the cases are classified as localized lesions while 29.3% are resulted in the identification of novel therapeutic targets, locally advanced and 47.2% are metastatic. The 5-year shifting the interest of cancer researchers from traditional survival rate for patients with localized lesions is 15.2% while chemotherapy to targeted (14, 20). for locally advanced and metastatic disease is 6.3% and 1.6% respectively (6). In addition to palliative surgery, At present, there are 58 known human receptor chemotherapy is also used to alleviate symptoms and, in some tyrosine kinases (RTKs) which have been divided into 20 patients, it can also prolong survival (7). Until 1997, 5- subfamilies (18). One of the best characterised RTK Fluoracil (5-FU) had been the only drug with clinical benefit in subfamily is the ErbB family which consists of four pancreatic cancer. The introduction of gemcitabine prolonged members namely; EGFR (also known as ErbB1/HER-1), median survival by approximately one month (5.65 vs 4.41 ErbB2 (neu/HER-2), ErbB3 (HER-3) and ErbB4 (HER-4) months, P=0.0025) and improved disease symptoms with a (21-23). All family members share a similar structure clinical benefit response rate of 23.8% compared to 4.8% of 5- comprising of a ligand-binding extracellular domain, a FU (P=0.0022) (8). As a result, gemcitabine was approved by transmembrane domain and a large cytoplasmic region with the United States Food and Drug Administration (FDA) for the tyrosine kinase activity. Interestingly, there are no known treatment of pancreatic cancer in May 1996 and since then, ligands for HER-2, while HER-3 has been characterized as despite numerous combinations of gemcitabine with other a tyrosine kinase-inactive receptor (21, 22, 24). However, agents in clinical trials, only erlotinib has been added to the recent evidence suggests that HER-3 is actually able to weaponry against advanced pancreatic cancer (9, 10). Erlotinib catalyse phosphorylation but with a much weaker efficacy (Tarceva), an epidermal growth factor receptor (EGFR) compared to the other HER family members (25, 26). To tyrosine kinase inhibitor (TKI), was the only agent which led date, 11 different growth factors have been identified which to a modest, but statistically significant, improvement in have the ability to bind to the extracellular domain of the median survival when used in combination with gemcitabine ErbB family members. These growth factors are compared to gemcitabine monotherapy (10, 11). categorized into three different groups based on their receptor specificity. The first group of ligands which bind The inefficiency of cytotoxic agents in the only to EGFR, consists of epidermal growth factor (EGF), treatment of pancreatic cancer is primarily due to the transforming growth factor-α (TGF-α), amphiregulin (AR) intrinsic drug resistance that characterizes pancreatic cancer and epigen (EPG); the second group of ligands, which (12). The lethal nature of the disease, combined with the binds to both EGFR and ErbB-4, includes epiregulin minimal improvement in prognosis and treatment during (EPR), betacellulin (BTC) and heparin-binding EGF (HB- the last decades, dictates the importance of the EGF). Neuregulins (NRGs), the third group, is divided into development of new therapeutic agents, as well as the two sub-groups; NRG-1 and NRG-2 which bind to both identification of more reliable tumour biomarkers for the ErbB-3 and ErbB-4 while NRG-3 and NRG-4 bind only to early diagnosis of pancreatic cancer, the categorization of ErbB-4 (27-29). The binding of a ligand to its respective different prognostic groups and for predicting the response receptor leads to conformational changes of the to therapy (13-15). The aim of this article is to review the extracellular domain which allow the formation of homo- role of the type-I growth factor receptor (also called HER, and/or heterodimers (30). The formation of dimers leads to ErbB) family and insulin-like growth factor receptor I the activation of the cytoplasmic kinase domains which in (IGF-IR) in the progression of pancreatic cancer and their turn results in the auto- and transphosphorylation of importance as prognostic and predictive biomarkers as specific tyrosine residues found on the C-terminal region of well as therapeutic targets in pancreatic cancer. each receptor. These phosphorylation events allow the recruitment of several intracellular proteins which contain a 3. HER/ERBB FAMILY MEMBERS AND THEIR Src homology 2 (SH2) or phosphotyrosine binding (PTB) LIGANDS IN PANCREATIC CANCER. domains like adaptor proteins Shc and Grb2, kinases like Src and phosphatidylinositol 3 kinase protein (PI3K) and 3.1.
Load more

Recommended publications
  • Human EGFR (Research Grade Matuzumab Biosimilar) Antibody
    Human EGFR (Research Grade Matuzumab Biosimilar) Antibody Recombinant Monoclonal Human IgG1 Clone # Hu104 Catalog Number: MAB10023 DESCRIPTION Species Reactivity Human Specificity Detects human EGFR based on Matuzumab therapeutic antibody. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Matuzumab. This product is for research use only. Source Recombinant Monoclonal Human IgG1 Clone # Hu104 Purification Protein A or G purified from cell culture supernatant Immunogen Human EGFR Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 μm filtered solution in PBS. APPLICATIONS Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website. Recommended Sample Concentration Flow Cytometry 0.25 µg/mL See Below CyTOF-ready Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation. DATA Flow Cytometry Detection of EGF R in A431 human epithelial carcinoma cell line by Flow Cytometry. A431 human epithelial carcinoma cell line was stained with Human Anti-Human EGF R (Research Grade Matuzumab Biosimilar) Monoclonal Antibody (Catalog # MAB10023, filled histogram) or irrelevant antibody (open histogram) followed by APC- conjugated Anti-Human IgG Secondary Antibody (Catalog # F0135). View our protocol for Staining Membrane-associated Proteins. PREPARATION AND STORAGE Reconstitution Reconstitute at 0.5 mg/mL in sterile PBS. Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
    [Show full text]
  • Nimotuzumab, an Antitumor Antibody That Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding While Permitting the Active Receptor Conformation
    Published OnlineFirst July 7, 2009; DOI: 10.1158/0008-5472.CAN-08-4518 Experimental Therapeutics, Molecular Targets, and Chemical Biology Nimotuzumab, an Antitumor Antibody that Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding while Permitting the Active Receptor Conformation Ariel Talavera,1,2 Rosmarie Friemann,2,3 Silvia Go´mez-Puerta,1 Carlos Martinez-Fleites,4 Greta Garrido,1 Ailem Rabasa,1 Alejandro Lo´pez-Requena,1 Amaury Pupo,1 Rune F. Johansen,3 Oliberto Sa´nchez,5 Ute Krengel,2 and Ernesto Moreno1 1Center of Molecular Immunology, Havana, Cuba; 2Department of Chemistry, University of Oslo, Oslo, Norway; and 3Center for Molecular and Behavioral Neuroscience, Institute of Medical Microbiology, University of Oslo, Rikshospitalet HF, Oslo, Norway; 4Department of Chemistry, University of York, Heslington, York, United Kingdom; and 5Center for Genetic Engineering and Biotechnology, Havana, Cuba Abstract region of the EGFR (eEGFR), leaving the dimerization ‘‘arm’’ in Overexpression of the epidermal growth factor (EGF) receptor domain II ready for binding a second monomer (4, 5). It has been (EGFR) in cancer cells correlates with tumor malignancy and shown that the eEGFR adopts a ‘‘tethered’’ or inactive conformation poor prognosis for cancer patients. For this reason, the EGFR in the absence of EGF (6). In this characteristic conformation, has become one of the main targets of anticancer therapies. the dimerization arm is hidden by interactions with domain IV, Structural data obtained in the last few years have revealed whereas domains I and III remain separated. Thus, to adopt the the molecular mechanism for ligand-induced EGFR dimeriza- ‘‘extended’’ or active conformation observed in the crystal structure tion and subsequent signal transduction, and also how this of the complex with EGF (4), the receptor must undergo a major signal is blocked by either monoclonal antibodies or small conformational change that brings together domains I and III (6).
    [Show full text]
  • Targeted and Novel Therapy in Advanced Gastric Cancer Julie H
    Selim et al. Exp Hematol Oncol (2019) 8:25 https://doi.org/10.1186/s40164-019-0149-6 Experimental Hematology & Oncology REVIEW Open Access Targeted and novel therapy in advanced gastric cancer Julie H. Selim1 , Shagufta Shaheen2 , Wei‑Chun Sheu3 and Chung‑Tsen Hsueh4* Abstract The systemic treatment options for advanced gastric cancer (GC) have evolved rapidly in recent years. We have reviewed the recent data of clinical trial incorporating targeted agents, including inhibitors of angiogenesis, human epidermal growth factor receptor 2 (HER2), mesenchymal–epithelial transition, epidermal growth factor receptor, mammalian target of rapamycin, claudin‑18.2, programmed death‑1 and DNA. Addition of trastuzumab to platinum‑ based chemotherapy has become standard of care as front‑line therapy in advanced GC overexpressing HER2. In the second‑line setting, ramucirumab with paclitaxel signifcantly improves overall survival compared to paclitaxel alone. For patients with refractory disease, apatinib, nivolumab, ramucirumab and TAS‑102 have demonstrated single‑agent activity with improved overall survival compared to placebo alone. Pembrolizumab has demonstrated more than 50% response rate in microsatellite instability‑high tumors, 15% response rate in tumors expressing programmed death ligand 1, and non‑inferior outcome in frst‑line treatment compared to chemotherapy. This review summarizes the current state and progress of research on targeted therapy for advanced GC. Keywords: Gastric cancer, Targeted therapy, Human epidermal growth factor receptor 2, Programmed death‑1, Vascular endothelial growth factor receptor 2 Background GC mortality which is consistent with overall decrease in Gastric cancer (GC), including adenocarcinoma of the GC-related deaths [4]. gastroesophageal junction (GEJ) and stomach, is the ffth Tere have been several eforts to perform large-scale most common cancer and the third leading cause of can- molecular profling and classifcation of GC.
    [Show full text]
  • Novel HER3 and IGF-1R Peptide Mimics and Synthetic Cancer Vaccines
    Novel HER3 and IGF-1R Peptide Mimics and Synthetic Cancer Vaccines DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Megan Miller Graduate Program in Microbiology The Ohio State University 2014 Dissertation Committee: Dr. Pravin Kaumaya, Advisor Dr. Larry Schlesinger Dr. Abhay Satoskar Dr. Nicanor Moldovan Copyright by Megan Miller 2014 Abstract Overexpression and constitutive activation of protein tyrosine kinases, including HER1 and HER2, are found in many human cancers and are critical factors in the development and malignancy of tumors. The downstream signaling networks of HER1 and HER2 have been extensively targeted by cancer therapeutics, and agents such as therapeutic monoclonal antibodies and small tyrosine kinase inhibitors (TKI) have been developed to block ligand binding, receptor dimerization, and intracellular tyrosine kinase activity. Drugs approved by the FDA include TKIs such as gefitinib and erlotinib and therapeutic monoclonal antibodies such as cetuximab, pertuzumab and trastuzumab. HER3 (ErbB3) and IGF-1R are receptor tyrosine kinases that have only recently been recognized as important for the development and progression of cancer. These receptors are frequently upregulated in cancer and also may provide routes for resistance to agents that target HER1 or HER2. Several recent studies have shown that HER3 and IGF-1R may be attractive targets against many types of cancer, including breast, ovarian, pancreatic, prostate, colon, head and neck, etc. Although there are no FDA approved therapies that target HER3 or IGF-1R, several monoclonal antibodies have been developed and are currently being evaluated in clinical trials.
    [Show full text]
  • Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
    cancers Review Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy Laura Boyero 1 , Amparo Sánchez-Gastaldo 2, Miriam Alonso 2, 1 1,2,3, , 1,2, , José Francisco Noguera-Uclés , Sonia Molina-Pinelo * y and Reyes Bernabé-Caro * y 1 Institute of Biomedicine of Seville (IBiS) (HUVR, CSIC, Universidad de Sevilla), 41013 Seville, Spain; [email protected] (L.B.); [email protected] (J.F.N.-U.) 2 Medical Oncology Department, Hospital Universitario Virgen del Rocio, 41013 Seville, Spain; [email protected] (A.S.-G.); [email protected] (M.A.) 3 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain * Correspondence: [email protected] (S.M.-P.); [email protected] (R.B.-C.) These authors contributed equally to this work. y Received: 16 November 2020; Accepted: 9 December 2020; Published: 11 December 2020 Simple Summary: Immuno-oncology has redefined the treatment of lung cancer, with the ultimate goal being the reactivation of the anti-tumor immune response. This has led to the development of several therapeutic strategies focused in this direction. However, a high percentage of lung cancer patients do not respond to these therapies or their responses are transient. Here, we summarized the impact of immunotherapy on lung cancer patients in the latest clinical trials conducted on this disease. As well as the mechanisms of primary and acquired resistance to immunotherapy in this disease. Abstract: After several decades without maintained responses or long-term survival of patients with lung cancer, novel therapies have emerged as a hopeful milestone in this research field.
    [Show full text]
  • 3356.Full.Pdf
    Cancer Therapy: Preclinical In vivo Therapeutic Synergism of Anti ^ Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas Christel Larbouret,1Bruno Robert,1Isabelle Navarro-Teulon,1Simon The' zenas,2 Maha-Zohra Ladjemi,1 Se¤ bastien Morisseau,1Emmanuelle Campigna,1Fre¤ de¤ ric Bibeau,3 Jean-Pierre Mach,5 Andre¤ Pe' legrin,1and David Azria1,4 Abstract Purpose: Pancreatic carcinoma is highly resistant to therapy. Epidermal growth factor receptor (EGFR) and HER2 have been reported to be both dysregulated in this cancer. To evaluate the in vivo effect of binding both EGFR and HER2 with two therapeutic humanized monoclonal anti- bodies (mAb), we treated human pancreatic carcinoma xenografts, expressing high EGFR and low HER2 levels. Experimental Design: Nude mice, bearing xenografts of BxPC-3 or MiaPaCa-2 human pan- creatic carcinoma cell lines, were injected twice weekly for 4 weeks with different doses of anti- EGFR (matuzumab) and anti-HER2 (trastuzumab) mAbs either alone or in combination.The effect of the two mAbs, on HER receptor phosphorylation, was also studied in vitro by Western blot analysis. Results: The combined mAb treatment significantly inhibited tumor progression of the BxPC-3 xenografts compared with single mAb injection (P =0.006)ornotreatment(P = 0.0004) and specifically induced some complete remissions. The two mAbs had more antitumor effect than 4-fold greater doses of each mAb. The significant synergistic effect of the two mAbs was con- firmed on the MiaPaCa-2 xenograft and on another type of carcinoma, SK-OV-3 ovarian carcino- ma xenografts. In vitro, the cooperative effect of the two mAbs was associated with a decrease in EGFR and HER2 receptor phosphorylation.
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • And Vascular Endothelial Growth Factor Receptor (VEGFR)
    molecules Review Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR) Nichole E. M. Kaufman 1, Simran Dhingra 1 , Seetharama D. Jois 2,* and Maria da Graça H. Vicente 1,* 1 Department of Chemistry, Louisiana State University, Baton Rouge, LA 70803, USA; [email protected] (N.E.M.K.); [email protected] (S.D.) 2 School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA * Correspondence: [email protected] (S.D.J.); [email protected] (M.d.G.H.V.); Tel.: +1-225-578-7405 (M.d.G.H.V.); Fax: +1-225-578-3458 (M.d.G.H.V.) Abstract: Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) are two extensively studied membrane-bound receptor tyrosine kinase proteins that are frequently overexpressed in many cancers. As a result, these receptor families constitute attractive targets for imaging and therapeutic applications in the detection and treatment of cancer. This review explores the dynamic structure and structure-function relationships of these two growth factor receptors and their significance as it relates to theranostics of cancer, followed by some of the common inhibition modalities frequently employed to target EGFR and VEGFR, such as tyrosine kinase inhibitors (TKIs), antibodies, nanobodies, and peptides. A summary of the recent advances Citation: Kaufman, N.E.M.; Dhingra, in molecular imaging techniques, including positron emission tomography (PET), single-photon S.; Jois, S.D.; Vicente, M.d.G.H. emission computerized tomography (SPECT), computed tomography (CT), magnetic resonance Molecular Targeting of Epidermal imaging (MRI), and optical imaging (OI), and in particular, near-IR fluorescence imaging using Growth Factor Receptor (EGFR) and tetrapyrrolic-based fluorophores, concludes this review.
    [Show full text]
  • Efficacy and Safety of Different Molecular Targeted Agents Based on Chemotherapy for Gastric Cancer Patients Treatment: a Network Meta-Analysis
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 29), pp: 48253-48262 Meta-Analysis Efficacy and safety of different molecular targeted agents based on chemotherapy for gastric cancer patients treatment: a network meta-analysis Zheng Ren1,*, Jinping Sun1,*, Xinfang Sun1, Hongtao Hou1, Ke Li1 and Quanxing Ge1 1Department of Digestive Internal Medicine, Huaihe Hospital of Henan University, Kaifeng 475000, Henan, China *These authors contributed equally to this work Correspondence to: Quanxing Ge, email: [email protected] Keywords: gastric cancer, molecular targeted agents, chemotherapy, network meta-analysis, efficacy Received: February 09, 2017 Accepted: March 23, 2017 Published: April 18, 2017 Copyright: Ren et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Increasing numbers of reports have been published to demonstrate that molecular targeted agents are able to improve the efficacy of chemotherapy in gastric cancer. This network meta-analysis aimed to evaluate the efficacy and safety of different molecular targeted agents, which were divided into six groups based on the targets including hepatocyte growth factor receptor (c-MET), vascular endothelial factor and its receptor (VEGF/VEGFR), human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), mammalian target of rapamycin (mTOR) and tyrosine kinase inhibitor (TKI). These six groups of targeted agents were evaluated for their efficacy outcomes measured by overall survival (OS), progression-free survival (PFS) and overall response rate (ORR). While their safety was measured 7 adverse events, including fatigue, anaemia, vomiting, neutropenia, thrombocytopenia, diarrhea and nausea.
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Antibodies to the Epidermal Growth Factor Receptor in Non ^ Small Cell
    Antibodies to the Epidermal Growth Factor Receptor in Non^SmallCellLungCancer:CurrentStatusof Matuzumab and Panitumumab Mark A. Socinski Abstract Matuzumab and panitumumab are antibodies against the epidermal growth factor receptor (EGFR) that are being evaluated in several malignancies including non ^ small cell lung cancer (NSCLC). In phase I trials of single-agent matuzumab in patients with EGFR-positive cancer, three tumor responses were documented in esophageal squamous cell carcinoma as well as colorectal carcinoma. A phase I trial of matuzumab in combination with paclitaxel has been reported in 18 patients with EGFR-positive advanced NSCLC. Objective responses were seen in 4 of 18 (23%) patients. A randomized phase II trial is currently ongoing in second-line NSCLC with matuzumab in combination with pemetrexed. A large dose/schedule trial of single-agent panitumumab enrolled 96 patients with EGFR-positive solid tumors. No responses were seen in the 14 lung cancer patients evaluated; 5 of 39 patients with colorectal cancers had objective responses. A randomized phase II trial of carboplatin/paclitaxel with or without panitumumab in 166 patients with previously untreated advanced stage IIIB/IV NSCLC did not find any benefit for the panitumumab arm compared with the chemotherapy alone arm with regard to response rates, time to disease progression, or median survival time. The lack of a biomarker to identify a subset of NSCLC patients who may derive benefit from this agent limits any potential enthusiasm for further trials of panitumumab at this time in NSCLC. Non–small cell lung cancer (NSCLC) remains the leading (frequently overproduced in malignancies) that bind to this cause of cancer-related mortality in the U.S.
    [Show full text]
  • A1090-Anti-EGFR
    BioVision rev 03/21 For research use only Anti-EGFR (Matuzumab), Human IgG1 Antibody CATALOG NO: A1090-50 50 µg REFERENCE: Murthy et al. Binding of an antagonistic monoclonal antibody to an intact A1090-100 100 µg and fragmented EGF-receptor polypeptide. Arch Biochem Biophys. 1987 Feb 1; 252 (2):549-60. ALTERNATIVE NAMES: Epidermal Growth Factor Receptor, Proto-oncogene c-ErbB-1 Receptor tyrosine-protein kinase erbB-1 RELATED PRODUCTS: IMMUNOGEN: Domain III of the extracellular domain of human EGFR Anti-VEGF (Bevacizumab), humanized Antibody (Cat. No. A1045-100) ISOTYPE / FORMAT: Human IgG1, kappa Anti-HER2 (Trastuzumab), humanized Antibody (Cat. No. A1046-100) CLONALITY: Monoclonal Anti-EGFR (Cetuximab), Chimeric Antibody (Cat. No. A1047-100) SPECIES REACTIVITY: Human Anti-TNF-α (Adalimumab), humanized Antibody (Cat. No. A1048-100) Anti-CD20 (Rituximab), Chimeric Antibody (Cat. No. A1049-100) FORM: Liquid Anti-EGFR (Panitumumab), humanized antibody (Cat. No. A1050-100) SOURCE: CHO cells Anti-OX40L (Oxelumab), Human IgG1 Antibody (Cat. No. A1088-200) FORMULATION: Supplied in PBS, pH 7.5 Anti-CD11a (Efalizumab), Human IgG1 Antibody (Cat. No. A1089-200) STORAGE CONDITIONS: Aliquot and store at -20 °C to -80 °C. Avoid repeated freeze-thaw Anti-CD4 (Clenoliximab), Human IgG4 Antibody (Cat. No. A1091-200) cycles Anti-alpha 5 beta1 Integrin (Volociximab), Human IgG4 Antibody (Cat. No. A1092- 200) DESCRIPTION: Recombinant monoclonal antibody to EGFR. Manufactured using recombinant technology with variable regions (i.e. specificity) from Anti-TNF alpha (Humicade), Human IgG4 Antibody (Cat. No. A1093-200) the therapeutic antibody Matuzumab. This antibody binds to Anti-CD40L (Ruplizumab), Human IgG1 Antibody (Cat.
    [Show full text]